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The pharmacokinetics of cefepime were studied in 10 male patients receiving continuous ambulatory
peritoneal dialysis therapy. Five patients received a single 1,000-mg dose and the other five received a single
2,000-mg dose; all doses were given as 30-min intravenous infusions. Serial plasma, urine, and peritoneal
dialysate samples were collected; and the concentrations of cefepime in these fluids were measured over 72 h
by using a high-performance liquid chromatographic assay with UV detection. Pharmacokinetic parameters
were calculated by noncompartmental methods. The peak concentrations in plasma and the areas under the
plasma concentration-versus-time curve for the 2,000-mg dose group were twice as high as those observed for
the 1,000-mg dose group. The elimination half-life of cefepime was about 18 h and was independent of the dose.
The steady-state volume of distribution was about 22 liters, and values for the 1,000- and 2,000-mg doses were
not significantly different. The values for total body clearance and peritoneal dialysis clearance were about 15
and 4 ml/min, respectively. No dose dependency was observed for the clearance estimates. Over the 72-h
sampling period, about 26% of the dose was excreted intact into the peritoneal dialysis fluid. For 48 h postdose,
mean concentrations of cefepime in dialysate at the end of each dialysis interval exceeded the reported MICs
for 90%o of bacteria which commonly cause peritonitis resulting from continuous peritoneal dialysis. A
parenteral dose of 1,000 or 2,000 mg of cefepime every 48 h would maintain the antibiotic levels in plasma and
peritoneal fluid above the MICs for 90% of the most susceptible bacteria for the treatment of systemic and
intraperitoneal infections.
Cefepime (BMY-28142) is a new parenteral cephalosporin
antibiotic with a broad antibacterial spectrum (7, 13) and a
low affinity for chromosomally mediated j3-lactamases (17,
22). Clinical experience indicates that cefepime is safe and
well tolerated. The pharmacokinetic properties of cefepime
are well documented (1, 2, 4-6). In normal male subjects,
cefepime has a mean elimination half-life (t1l2) of about 2.2 h
and obeys linear kinetics over an intravenous dose range of
250 to 2,000 mg (1, 2). Over 85% of the administered dose is
recovered in urine as intact cefepime in subjects with normal
kidney function (5). The safety, tolerance, and pharmacoki-
netics of cefepime have been evaluated in patients with renal
impairment, including those on hemodialysis, and dosing
regimen adjustments have been developed (4).
Continuous ambulatory peritoneal dialysis (CAPD) is a
self-dialysis procedure which is widely recommended as an
alternative to hemodialysis in the treatment of end-stage
renal disease (15, 18). However, peritonitis is a major and
often serious complication of CAPD. Approximately 60% of
patients undergoing CAPD develop peritonitis within the
first year of the initiation of dialysis (16). Bacterial peritonitis
is generally caused by catheter contamination by common
skin organisms. The antibacterial spectrum of cefepime
covers the bacteria known to cause CAPD-induced perito-
nitis (16, 21). In light of its excellent antimicrobial charac-
teristics, cefepime is a useful addition to the armamentarium
for the treatment of peritonitis and other systemic infections
in patients undergoing CAPD.
This study was designed to characterize the safety, toler-
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ance, and pharmacokinetic characteristics of cefepime and
to investigate the extent of peritoneal cavity entry of
cefepime following intravenous administration of single
1,000- and 2,000-mg doses to patients undergoing CAPD.
Another objective was to develop a dosage schedule for the
use of intravenous cefepime in patients undergoing CAPD.
MATERIALS AND METHODS
Patients. A total of 10 patients undergoing CAPD who did
not have evidence of peritonitis and who had no known
hypersensitivity to ,-lactam antibiotics participated in the
study after signing an informed consent form. This protocol
was approved by the Committee for the Protection of the
Rights of Human Subjects of the Medical School of the
University of North Carolina at Chapel Hill. The patients
had a mean + standard deviation age of 56 + 11 years, a
mean body weight of 78 + 15 kg, and a mean height of 176 +
5 cm. The creatinine clearance (CLCR) values for seven
patients were less than 0.52 ml/min. The remaining three
patients had CLCR values of 1.77, 2.21, and 3.44 ml/min.
None of the patients had experienced peritonitis in the
1-month period prior to entry into the study. A physical
examination and a laboratory screening profile were per-
formed on each patient before and after the study. All
patients had normal liver functions, as determined by routine
laboratory liver function tests, and hematologic profiles were
normal except for the anemia resulting from chronic renal
failure. The patients were not allowed to take any medica-
tion unless it was approved by the principal investigator.
Beverages containing alcohol or caffeine also were not
permitted during the confinement period in the General
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Clinical Research Center of the University of North Caro-
lina, which began at least 12 h prior to dosing and which
ended 96 h after dosing. The patients were randomly as-
signed to the 1,000- or 2,000-mg dose group. There were five
patients in each dose group.
Each patient had a long-term indwelling catheter. The
CAPD exchange schedule for each patient was 2 liters of
2.5% glucose peritoneal dialysis solution (Dianeal; Travenol
Laboratories, Inc., Deerfield, Ill.) approximately every 6 h
during the day. Dwell times of as long as 10 h were used
overnight.
Drug formulation and administration. Vials containing a
dry-fill powder blend of cefepime dihydrochloride and
L-arginine were supplied by the Pharmaceutical Product
Development Department, Bristol-Myers Squibb Pharma-
ceutical Research Institute, Syracuse, N.Y. Each 1-g vial
was reconstituted with 2.8 ml of preservative-free sterile
water for injection; this provided a total volume of 4.1 ml of
solution containing 250 mg of cefepime per ml. For the
1,000-mg dose level, 6 ml of the reconstituted solution was
mixed with 69 ml of sterile saline solution to prepare an
infusion solution containing 20 mg of cefepime per ml. For
the 2,000-mg dose level, 12 ml of the reconstituted solution
was mixed with 63 ml of sterile saline solution to prepare an
infusion solution containing 40 mg of cefepime per ml.
Each cefepime dose was administered as a constant-rate
infusion into a forearm vein by means of a syringe infusion
pump calibrated to deliver 50 ml of infusion solution in the
30-min infusion interval.
Sample collection. Approximately 5 ml of heparinized
blood was drawn from the contralateral forearm vein of
every patient immediately predose (zero time) and at 10, 20,
30, 33, 39, and 45 min and 1, 1.5, 2, 4, 6, 8, 10, 12, 15, 18, 30,
36, 39, 48, 60, and 72 h after the start of infusion. Each blood
sample was gently inverted a few times for complete mixing
and was then placed in a bath of chipped ice. Within 30 min
of collection, each sample was centrifuged at 1,000 x g for
15 min and 5°C to separate the plasma. The plasma samples
were transferred to appropriately labeled screw-cap polypro-
pylene test tubes and were stored frozen at or below -20°C.
Samples of dialysis fluid of approximately 10 ml were
collected immediately before dosing (zero time) and at 0.25,
0.50, 1, 2, 3, 4, and 6 h after the start of infusion. To ensure
that these samples were taken from intraperitoneal dialyzing
fluid, 50 ml of dialysate was aseptically withdrawn from the
dialysis tubing. This fluid was approximately 20 ml in excess
of that volume found to occupy dead space in the dialysis
catheter and connecting tubing. After collecting the dialysate
sample, the initial 50 ml of dialysate was reinfused into the
tubing to refill the dead space. At the time of exchange of this
dialysate, its total volume was measured and recorded. For
all subsequent dialyses, the total dialysate volume was
measured and recorded and a 10-ml dialysate sample was
collected at the time of exchange. Exactly 10 ml of each
dialysate sample was mixed with 20 ml of 0.2 M sodium
acetate buffer (pH 4.25) and frozen in appropriately labeled
screw-cap 50-ml polypropylene tubes. The samples were
stored at or below -20°C.
Total urine voided over the intervals of 0 to 12, 12 to 24, 24
to 48, and 48 to 72 h after the start of dosing was collected
from the patients who were not anuric. The collection
vessels were kept refrigerated over each interval when they
were not in use. At the end of each interval, the urine sample
was mixed and the pH and total volume were recorded. A
3.0-ml portion of the urine sample was transferred to an
appropriately labeled 15-ml screw-cap polypropylene tube,
and 6.0 ml of 0.2 M sodium acetate buffer (pH 4.25) was
added. These urine samples were frozen and stored at or
below -20°C.
Creatinine concentrations in plasma and urine were mea-
sured for the determination of CLCR by using a Gilson
clinical analyzer system. For each patient, a 12-h CLCR
normalized to a 1.73-M2 body surface area was measured
immediately before dosing (-12 to 0 h).
Drug analysis. Plasma and urine samples were analyzed
for intact cefepime by using validated high-performance
liquid chromatographic assays with UV detection (3).
Cefepime was quantitated in buffered dialysate by using the
assay conditions for plasma. Quality-control samples were
prepared in each biological matrix before initiation of the
study to verify storage stability as well as the accuracy and
precision of each cefepime assay sequence.
Standard curves of cefepime in plasma and dialysate were
linear within the range of 0.5 to 50.0 ,ug/ml, and those in
urine were linear within the range of 2.0 to 1,000 p,g/ml. The
lower limit of quantitation of cefepime in each biological
fluid was established at the lowest concentration of the
standard curves. Quality-control samples that contained
known concentrations of cefepime were prepared in each
biological fluid prior to the initiation of drug administration
at each dose level. A coefficient of variation of consistently
less than 9% for the quality-control samples suggests that the
assays for cefepime in plasma, dialysate, and urine were
accurate and precise. The between-day coefficients of vari-
ation for quality-control samples of cefepime in plasma at
concentrations of 2.0 (n = 15), 40 (n = 12), and 140 (n = 12)
p,g/ml were 9, 9, and 7.4%, respectively, where n is the
number of replicates of the quality-control sample. The
between-day coefficients of variation for quality-control
samples of cefepime in urine at concentrations of 10 (n = 3),
500 (n = 3), and 1,000 (n = 3) ,ug/ml were 4.4, 2.1, and 3.2%,
respectively.
Pharmacokinetic analysis. Plasma cefepime concentration-
versus-time data were evaluated by noncompartmental
methods (8, 19). The highest observed concentration in
plasma (Cm.) and the corresponding sampling time were
determined. The elimination half-life (t1l2) was calculated as
(ln 2)/b, where b is the absolute value of the slope of the
least-squares regression line for n-terminal datum points.
These datum points (n > 3) were selected to minimize the
mean-square error term for the regression. The area under
the plasma concentration-versus-time curve (AUC) and the
area under the first moment of the plasma concentration-
versus-time curve (AUMC) were calculated by using a
combination of linear and log trapezoidal rules. The log
trapezoidal rule was used when concentration data were in
an exponentially declining phase. The AUC from the last
point to infinity was estimated by dividing the last measured
concentration by the elimination rate constant. The mean
residence time (MRT) in the body was estimated as follows:
MRT = AUMC0JAUC_O,, where AUMC.O, is the AUMC
from time zero to infinity, and AUCO 0 is the AUC from time
zero to infinity. The MRT equivalent for bolus intravenous
administration [MRT(i.v.)] was calculated as follows: MRT
(i.v.) = MRT - (T/2), where T is the infusion time (0.50 h).
Total body clearance (CL) was calculated as CL = dose/
AUC,,. The steady-state volume of distribution (V.,) was
obtained as follows: V,, = MRT(i.v.). CL. The amount of
intact cefepime excreted during each collection interval was
calculated as the product of the concentration in the corre-
sponding buffered urine sample and the total volume of urine
voided in that interval. Total urinary recovery was calcu-
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FIG. 1. Mean plasma concentration-versus-time profiles of
cefepime following 1,000-mg (e) and 2,000-mg (O) intravenous
doses to patients undergoing CAPD.
lated as the cumulative amount excreted within the collec-
tion period and was expressed as a percentage of the
administered dose. The renal clearance of cefepime (CLR)
was calculated as CLR = X,,/AUCGoO, where X,, is the
amount of cefepime excreted in urine.
T'he amount of intact cefepime excreted in peritoneal
dialysate during each dialysis interval was calculated as the
product of the concentration in the coffesponding buffered
dialysis fluid sample and the total volume of dialysis fluid
recovered at the end of that interval. The total amount of
drug recovered from dialysis rfluid was calculated as the
cumulative amount excreted within the 72-h collection pe-
riod and was expressed as a percentage of the administered
dose. Dialytic clearance of cefepime (CLD) was calculated as
CLD = XD/AUCG_:, where XD is the amount of cefepime
excreted in dialysate.
Statistical analysis. The mean values of the pharmacoki-
netic parameters between the two dose level groups were
compared by using the two-sample t test. The variances of
the two samples were tested for equality by a two-sample F
test. If the variances had been found to be unequal, the
Welch t test would have been used instead of the usual
two-sample t test. All statistical analyses were tested for
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FIG. 2. Mean dialysate concentrations of cefepime following
1,000-mg (-) and 2,000-mg (O) intravenous doses.
RESULTS
Safety and tolerance. There were no abnormal laboratory
values related to cefepime therapy; the abnormal values
observed were consistent with the prestudy values and were
consequences of patient renal impairment. The drug was
well tolerated by each patient.
Pharmacokinetics. Mean plasma cefepime concentration-
versus-time profiles following administration of the 1,000-
and 2,000-mg doses are shown in Fig. 1. The penetration of
cefepime into the peritoneal cavity was rapid. The average
concentrations of cefepime were 8.8 and 16.5 ,ug/ml 1 h after
administration of the 1,000- and 2,000-mg doses, respec-
tively. The maximum concentrations of cefepime in perito-
neal dialysate, 27.0 and 60.7 ,ug/ml, were observed 6 h after
intravenous administration of the 1,000- and 2,000-mg doses,
respectively (Fig. 2). Over the 72-h observation period,
about 25% of the administered dose was excreted into the
peritoneal dialysis fluid. Less than 5% of the dose was
recovered in urine as intact cefepime.
Pharmacokinetic data for individual patients and their
mean values by dose group are given in Table 1. The values
for Cmax, and AUC for the 2,000-mg dose group were twice as
high as those observed in the 1,000-mg dose group. Tle t1/2
of cefepime was about 18 h in patients undergoing CAPD and
was independent of the dose. The V.., of cefepime was about
TABLE 1. Pharmacokinetics of cefepime in patients undergoing CAPD following single 1,000- and 2,000-mg doses
Dose (mg) Subject CMc MRT t1 AUC}O CL CLR CLD V.sno. (1Lg/ml) (h) (h) (jig * h/ml) (mlmin) (ml/min) (ml/min) (liters)
1,000 1 51.9 24.6 17.2 991 16.8 0 4.34 24.8
2 77.6 24.6 16.7 1,245 13.4 0.89 3.50 19.8
3 75.7 21.6 15.4 1,177 14.2 1.50 4.35 18.4
4 68.1 28.6 22.6 1,691 9.9 0.10 3.01 17.0
5 41.1 20.6 16.0 724 23.0 2.50 4.11 28.4
Mean + SD 62.9 ± 15.8 24.0 + 3.1 17.6 ± 2.9 1,166 - 356 15.4 ± 4.9 1.00 ± 1.04 3.86 ± 0.59 21.7 ± 4.8
2,000 6 140 27.2 19.2 2,563 13.0 0 4.00 21.2
7 120 28.0 19.4 2,495 13.4 0.12 5.14 22.5
8 107 28.4 20.4 2,202 15.1 0.29 4.54 25.7
9 115 25.0 16.2 2,151 15.5 0.61 3.36 23.2
10 135 25.6 18.9 2,611 12.8 0.20 4.72 19.7
Mean t SD 124 ± 14 26.8 ± 1.5 18.8 ± 1.6 2,405 - 213 14.0 ± 1.3 0.24 t 0.23 4.35 t 0.69 22.5 t 2.8
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22 liters and was independent of the dose. The values for CL
and CLD were approximately 15 and 4 ml/min, respectively,
and no dose dependency was observed for the clearance
estimates.
DISCUSSION
All 10 patients in this study were in end-stage renal failure
that required dialysis and could be regarded as a relatively
homogeneous group. The values for V,, in the patients in the
present study were almost identical to those observed in
previous studies of cefepime in subjects with normal renal
function (1, 2) and various degrees of renal insufficiency (4,
5). The data that we obtained in the present study support
and extend the findings of the previous studies, namely, that
renal impairment does not affect the distribution of cefepime
in the body.
As a route of elimination of systemically administered
cefepime, CAPD appears to be a less efficient process than
hemodialysis. The CLD of cefepime in the present study was
about 9% of that reported for patients on hemodialysis (4). If
it were necessary to remove cefepime from the body as
rapidly as possible, as in the case of overdosage, hemodial-
ysis should be used.
The CLD of cefepime (about 4 ml/min) is higher than those
reported for ceftizoxime (3 ml/min), ceftriaxone (0.69 ml/
min), cefoperazone (0.55 ml/min), and cefotaxime (1.7 ml/
min) and is similar to that reported for ceftazidime (9-11, 14,
22). It is expected that antibiotics with larger CLD values
would have relatively higher concentrations in dialysis fluid.
The bacteria that are commonly found to cause peritonitis in
patients undergoing CAPD (24) and the susceptibilities of
these bacteria to cefepime (13), stated as the MIC for 90% of
strains tested, are as follows: Staphylococcus epidermis, 0.5
pg/ml; Staphylococcus aureus (penicillinase producers), 1.9
,ug/ml; Streptococcus spp., 0.05 ,ug/ml; Escherichia coli, 0.2
,g/ml; and Pseudomonas aeruginosa, 7.0 ,ug/ml. For at least
48 h after a 2,000-mg dose, the mean concentrations of
cefepime in dialysate at the end of each dialysate interval
exceeded the MICs for 90% of these bacteria.
For treatment of systemic infections in patients with
normal renal function, cefepime is administered two or three
times a day. If the dose administered in patients undergoing
CAPD is the same as that used in patients with normal renal
function, the dosing interval (T) in patients undergoing
CAPD can be calculated by using the following equation: Tc
=CL(r) Tr/CLc, where the subscripts r and c are for the
values in patients with normal kidney function and patients
undergoing CAPD, respectively.
By using the mean values for CL in patients undergoing
CAPD (14.7 ml/min) and individuals with normal renal
function (130 ml/min) and an 8-h dosing interval in patients
with normal kidney function, a dosing interval of 70.7 h is
calculated for patients undergoing CAPD. This calculation is
supported by the observation that, for the 1,000-mg dose, the
cefepime levels in plasma at 72 h in patients undergoing
CAPD in the present study and at 8 h in individuals with
normal renal function (2) are similar. Therefore, for the
treatment of systemic infections in patients undergoing
CAPD, a cefepime dosage once every 72 h at a 1,000- or
2,000-mg dose level would maintain levels of drug in blood
equivalent to those with dosing once every 8 h in patients
with normal renal function.
The present study was carried out in patients undergoing
CAPD but who did not have peritonitis. Peritoneal transfer
of some antibiotics (12) and some endogenous substances
such as urea and creatinine (20) may be altered in the
presence of inflamed peritoneal membranes during peritoni-
tis. The clinical relevance of a possible alteration in the
pharmacokinetics of cefepime, a cephalosporin with a wide
therapeutic margin, in patients with peritonitis undergoing
CAPD is questionable. However, further studies of cefepime
in patients with and without documented peritonitis under-
going CAPD may be necessary to characterize the effects of
peritonitis on the pharmacokinetics of cefepime following an
intraperitoneal dose.
Results of the present study suggest that cefepime is safe
and well tolerated in patients undergoing CAPD. A parent-
eral dose of 1,000 or 2,000 mg every 48 h would maintain
therapeutic levels of cefepime in plasma and peritoneal fluid
for the treatment of systemic and intraperitoneal infections
caused by susceptible bacteria, but it would not cause an
excessive accumulation of the cephalosporin.
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